Jeremy Huff, DO
Internal Medicine · Beaumont, TXNPI 1982802419
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,341 of the $4,876 with a category attached, or 89.0%. It is spread thinly across 46 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,211, 2.4 times the $515 reported in 2019. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$636
- AbbVie$495
- AstraZeneca$494
- Novartis$328
- GSK$306
- Pfizer$246
- plus $2K from 40 others
What the payments were for
- Travel & lodging$53411%
- Food & beverage$4,34189%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$525
- XARELTO$122
- BEVESPI AEROSPHERE$109
- FARXIGA$109
- DAXXIFY$104
How this compares
$4,876 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 804 | $386,798 |
| OzempicSemaglutide | 211 | $226,789 |
| MounjaroTirzepatide | 177 | $211,784 |
| XareltoRivaroxaban | 200 | $117,716 |
| JardianceEmpagliflozin | 149 | $116,009 |
| MyrbetriqMirabegron | 211 | $93,202 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 105 | $92,412 |
| JanuviaSitagliptin Phosphate | 103 | $61,005 |
| TrulicityDulaglutide | 54 | $59,390 |
| NuplazidPimavanserin Tartrate | 11 | $58,002 |
| FarxigaDapagliflozin Propanediol | 88 | $40,691 |
| EntrestoSacubitril/Valsartan | 73 | $33,843 |
| LinzessLinaclotide | 47 | $31,035 |
| Divalproex Sodium | 197 | $27,508 |
| Memantine Hcl | 320 | $23,792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $246 | $386,798804 claims |
| Lilly USA, LLCMounjaro, Trulicity | $14 | $271,175231 claims |
| Novo NordiskOzempic, Rybelsus, Fiasp | $199 | $258,442277 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $306 | $125,319172 claims |
| Johnson & JohnsonXarelto | $122 | $117,716200 claims |
| Boehringer IngelheimJardiance | $51 | $116,009149 claims |
| MerckJanuvia, Janumet Xr | $66 | $82,818120 claims |
| AbbVieLinzess, Synthroid, Restasis | $495 | $52,514248 claims |
| AstraZenecaFarxiga | $494 | $40,69188 claims |
| NovartisEntresto | $328 | $33,84373 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $12 | $21,6691,738 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Beaumont
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.